Published in Pharma Investments, Ventures and Law Weekly, February 26th, 2006
The increase in revenues was primarily attributable to net sales of Cubicin (daptomycin for injection), which increased 94% compared to 2004 to $113.5 million in 2005.
Net loss for the fourth quarter of 2005 was $6.7 million or $0.12 per share, as compared to $17.7 million, or $0.40 per share for the fourth quarter of 2004. For 2005, net loss was $31.9 million or $0.60 per share as compared to $76.5 million or $1.86 per share in 2004.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.